| Title |
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer
|
|---|---|
| Published in |
Breast Cancer Research, June 2018
|
| DOI | 10.1186/s13058-018-0974-2 |
| Pubmed ID | |
| Authors |
Erin D. Giles, Sonali Jindal, Elizabeth A. Wellberg, Troy Schedin, Steven M. Anderson, Ann D. Thor, Dean P. Edwards, Paul S. MacLean, Pepper Schedin |
| Abstract |
Obesity and type II diabetes are linked to increased breast cancer risk in postmenopausal women. Patients treated with the antidiabetic drug metformin for diabetes or metabolic syndrome have reduced breast cancer risk, a greater pathologic complete response to neoadjuvant therapy, and improved breast cancer survival. We hypothesized that metformin may be especially effective when targeted to the menopausal transition, as this is a lifecycle window when weight gain and metabolic syndrome increase, and is also when the risk for obesity-related breast cancer increases. Here, we used an 1-methyl-1-nitrosourea (MNU)-induced mammary tumor rat model of estrogen receptor (ER)-positive postmenopausal breast cancer to evaluate the long-term effects of metformin administration on metabolic and tumor endpoints. In this model, ovariectomy (OVX) induces rapid weight gain, and an impaired whole-body response to excess calories contributes to increased tumor glucose uptake and increased tumor proliferation. Metformin treatment was initiated in tumor-bearing animals immediately prior to OVX and maintained for the duration of the study. Metformin decreased the size of existing mammary tumors and inhibited new tumor formation without changing body weight or adiposity. Decreased lipid accumulation in the livers of metformin-treated animals supports the ability of metformin to improve overall metabolic health. We also found a decrease in the number of aromatase-positive, CD68-positive macrophages within the tumor microenvironment, suggesting that metformin targets the immune microenvironment in addition to improving whole-body metabolism. These findings suggest that peri-menopause/menopause represents a unique window of time during which metformin may be highly effective in women with established, or at high risk for developing, breast cancer. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 68 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 15% |
| Researcher | 6 | 9% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Bachelor | 6 | 9% |
| Student > Doctoral Student | 5 | 7% |
| Other | 10 | 15% |
| Unknown | 25 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 21% |
| Agricultural and Biological Sciences | 5 | 7% |
| Nursing and Health Professions | 3 | 4% |
| Veterinary Science and Veterinary Medicine | 3 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Other | 11 | 16% |
| Unknown | 29 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2018.
All research outputs
#14,393,794
of 25,382,440 outputs
Outputs from Breast Cancer Research
#1,253
of 2,054 outputs
Outputs of similar age
#166,351
of 341,958 outputs
Outputs of similar age from Breast Cancer Research
#23
of 37 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,054 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,958 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.